Zobrazeno 1 - 10
of 835
pro vyhledávání: '"Robert M Grant"'
Publikováno v:
Journal of Medical Internet Research, Vol 23, Iss 7, p e22650 (2021)
BackgroundHIV pre-exposure prophylaxis (PrEP) is a way to prevent HIV infection using antiretroviral medications. However, common barriers to PrEP engagement include lack of access to prescribers; discomfort seeking sexual health services; and racism
Externí odkaz:
https://doaj.org/article/cde6cde66b5c40c19fc6f7b42ed80a9b
Publikováno v:
PLoS ONE, Vol 14, Iss 3, p e0213167 (2019)
BackgroundEarly initiation of antiretroviral therapy (eiART) can improve clinical outcomes for persons with HIV and reduce onward transmission risk. Baseline drug resistance testing (bDRT) can inform regimen selection upon subsequent treatment initia
Externí odkaz:
https://doaj.org/article/7ea9fb5787b44901b8499d4385460a38
Autor:
Dominique B Figueroa, Joseph Tillotson, Maoji Li, Estelle Piwowar-Manning, Craig W Hendrix, Timothy H Holtz, Kevin Bokoch, Linda-Gail Bekker, Frits van Griensven, Sharon Mannheimer, James P Hughes, Robert M Grant, Namandjé N Bumpus
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0195764 (2018)
Tenofovir (TFV), a nucleotide reverse transcriptase inhibitor, requires two phosphorylation steps to form a competitive inhibitor of HIV reverse transcriptase. Adenylate kinase 2 (AK2) has been previously demonstrated to phosphorylate tenofovir to te
Externí odkaz:
https://doaj.org/article/5c4afdf43275489faacaf0ba13a21d5d
Publikováno v:
PLoS Pathogens, Vol 3, Iss 10, Pp 1477-1485 (2007)
The evolutionary success of primate lentiviruses reflects their high capacity to mutate and adapt to new host species, immune responses within individual hosts, and, in recent years, antiviral drugs. APOBEC3G (A3G) and APOBEC3F (A3F) are host cell DN
Externí odkaz:
https://doaj.org/article/ca2fae4f57d4478f93ff1e2b0fcb38f0
Autor:
Julia L Marcus, David V Glidden, Vanessa McMahan, Javier R Lama, Kenneth H Mayer, Albert Y Liu, Orlando Montoya-Herrera, Martin Casapia, Brenda Hoagland, Robert M Grant
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e91513 (2014)
In addition to protecting against HIV acquisition, antiretroviral preexposure prophylaxis (PrEP) using topical 1% tenofovir gel reduced Herpes simplex virus type 2 (HSV-2) acquisition by 51% among women in the CAPRISA 004 study. We examined the effec
Externí odkaz:
https://doaj.org/article/1083d805b37c41de939df022c8322ddb
Autor:
Julia L Marcus, David V Glidden, Kenneth H Mayer, Albert Y Liu, Susan P Buchbinder, K Rivet Amico, Vanessa McMahan, Esper Georges Kallas, Orlando Montoya-Herrera, Jose Pilotto, Robert M Grant
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e81997 (2013)
Preexposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) reduced HIV acquisition in the iPrEx trial among men who have sex with men and transgender women. Self-reported sexual risk behavior decreased overall, but may
Externí odkaz:
https://doaj.org/article/7de4410a9b2142d0aa0de002a442f7c9
Autor:
Snigdha Vallabhaneni, J Jeff McConnell, Lisa Loeb, Wendy Hartogensis, Fredrick M Hecht, Robert M Grant, Christopher D Pilcher
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e55397 (2013)
We assessed changes in sexual behavior among men who have sex with men (MSM), before and for several years after HIV diagnosis, accounting for adoption of a variety of seroadaptive practices.We collected self-reported sexual behavior data every 3 mon
Externí odkaz:
https://doaj.org/article/56f95384a97c4812ab9fe6e856e043af
Autor:
Gabriela B Gomez, Annick Borquez, Carlos F Caceres, Eddy R Segura, Robert M Grant, Geoff P Garnett, Timothy B Hallett
Publikováno v:
PLoS Medicine, Vol 9, Iss 10, p e1001323 (2012)
HIV pre-exposure prophylaxis (PrEP), the use of antiretroviral drugs by uninfected individuals to prevent HIV infection, has demonstrated effectiveness in preventing acquisition in a high-risk population of men who have sex with men (MSM). Consequent
Externí odkaz:
https://doaj.org/article/0c515a14630f4afdad0751753b143da1
Autor:
Hong-Ha M Truong, Timothy A Kellogg, Willi McFarland, Brian Louie, Jeffrey D Klausner, Susan S Philip, Robert M Grant
Publikováno v:
PLoS ONE, Vol 6, Iss 10, p e25281 (2011)
HIV-1 acute infection, recent infection and transmitted drug resistance screening was integrated into voluntary HIV counseling and testing (VCT) services to enhance the existing surveillance program in San Francisco. This study describes newly-diagno
Externí odkaz:
https://doaj.org/article/1c9581dc9afa49939ede99352f9c6f6d
Autor:
Vivek Jain, Teri Liegler, Eric Vittinghoff, Wendy Hartogensis, Peter Bacchetti, Lauren Poole, Lisa Loeb, Christopher D Pilcher, Robert M Grant, Steven G Deeks, Frederick M Hecht
Publikováno v:
PLoS ONE, Vol 5, Iss 12, p e15510 (2010)
Transmitted HIV-1 drug resistance (TDR) is an ongoing public health problem, representing 10-20% of new HIV infections in many geographic areas. TDR usually arises from two main sources: individuals on antiretroviral therapy (ART) who are failing to
Externí odkaz:
https://doaj.org/article/407e73538f0c4802a0f3532ff3791893